Graybill, W. S., Vergote, I., Pothuri, B., Anttila, M., O’Malley, D. M., Lorusso, D., . . . Gonzalez-Martin, A. Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer. Becaris Publishing Limited.
Chicago Style (17th ed.) CitationGraybill, Whitney S., et al. Use of Individualized Starting Dose and Niraparib Hematologic Adverse Event Management Costs in Ovarian Cancer. Becaris Publishing Limited.
MLA (9th ed.) CitationGraybill, Whitney S., et al. Use of Individualized Starting Dose and Niraparib Hematologic Adverse Event Management Costs in Ovarian Cancer. Becaris Publishing Limited.
Warning: These citations may not always be 100% accurate.